U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C10H14O4
Molecular Weight 198.2161
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GUAIFENESIN

SMILES

COc1ccccc1OCC(CO)O

InChI

InChIKey=HSRJKNPTNIJEKV-UHFFFAOYSA-N
InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3

HIDE SMILES / InChI
Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions. Guaifenesin is over-the-counter drug for the treatment of cough and common cold.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
MUCINEX

Approved Use

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

Launch Date

1.02643198E12
Palliative
MUCINEX

Approved Use

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

Launch Date

1.02643198E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GUAIFENESIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.2 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GUAIFENESIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GUAIFENESIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Other AEs: Headache, Sore throat...
Other AEs:
Headache
Sore throat
Indigestion
Nose bleed
Eye infection
Sources:
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Other AEs: Headache, Sore throat...
Other AEs:
Headache
Sore throat
Indigestion
Nose bleed
Eye infection
Sources:
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 63.7 years
n = 12
Health Status: unhealthy
Condition: filamentary keratitis
Age Group: 63.7 years
Sex: M+F
Population Size: 12
Sources:
Disc. AE: Vomiting, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Vomiting (1 patient)
Diarrhea (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Eye infection
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Headache
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Indigestion
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Nose bleed
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Sore throat
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Eye infection
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Headache
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Indigestion
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Nose bleed
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Sore throat
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
healthy, 31. 3 years (range: 19–50 years)
n = 24
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Population Size: 24
Sources:
Diarrhea 1 patient
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 63.7 years
n = 12
Health Status: unhealthy
Condition: filamentary keratitis
Age Group: 63.7 years
Sex: M+F
Population Size: 12
Sources:
Vomiting 1 patient
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 63.7 years
n = 12
Health Status: unhealthy
Condition: filamentary keratitis
Age Group: 63.7 years
Sex: M+F
Population Size: 12
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Potentiating effects of chlorpromazine on the paralysis and toxicity induced by guaiacal glyceryl ether in rats.
1972 Dec
Hypertension in bulls and steers anesthetized with guaifenesin-thiobarbiturate-halothane combination.
1986 Jul
Affective disorder following use of phenylpropanolamine.
1990 Mar
Fulminant hepatic failure associated with clarithromycin.
1996 Feb
Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis.
1999 Jul
Guaifenesin- and ephedrine-induced stones.
1999 Nov
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Ephedrine- and guaifenesin-induced nephrolithiasis.
2004 Dec
Bilateral guaifenesin ureteral calculi.
2004 Jan
Spontaneous dissolution of a guaifenesin stone.
2005 Aug
Dextromethorphan-induced delirium and possible methadone interaction.
2005 Mar
Pseudoephedrine and guaifenesin urolithiasis: widening the differential diagnosis of radiolucent calculi on abdominal radiograph.
2005 Sep-Oct
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Guaifenesin can also be given in syrup form.
1 tablet every 12 hours (adults and children 12 years of age and over).
Route of Administration: Oral
In Vitro Use Guide
Sputum or mucus simulants were analyzed untreated and after the addition of guaifenesin at 1:5 volume to volume ratio for a contact period of 60 s. The concentration of guaifenesin was 20 mg/mL.
Name Type Language
GUAIFENESIN
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
FLOWTUSS COMPONENT GUAIFENESIN
Brand Name English
GUAIFENESIN [USP-RS]
Common Name English
GUAIFENESIN [HSDB]
Common Name English
GUAIFENESIN COMPONENT OF FLOWTUSS
Brand Name English
HYCOFENIX COMPONENT OF GUAIFENESIN
Brand Name English
MUCINEX
Brand Name English
(+/-)-3-(O-METHOXYPHENOXY)-1,2-PROPANEDIOL
Common Name English
METHPHENOXYDIOL
Common Name English
MUCINEX D COMPONENT GUAIFENESIN
Common Name English
GUAIFENESIN COMPONENT OF MUCINEX D
Common Name English
GUAIFENESIN COMPONENT OF OBREDON
Brand Name English
GUAIFENESIN [GREEN BOOK]
Common Name English
GUAIFENESIN [MART.]
Common Name English
GUAIFENESIN [MI]
Common Name English
GUAIFENESIN [EP MONOGRAPH]
Common Name English
HUSTOSIL
Brand Name English
MUCINEX DM COMPONENT GUAIFENESIN
Common Name English
CVT-2534
Code English
OBREDON COMPONENT GUAIFENESIN
Brand Name English
GLYCERYL GUAIACOLATE
Systematic Name English
GUAIFENESIN COMPONENT OF HYCOFENIX
Brand Name English
GUAIFENESIN [USAN]
Common Name English
NSC-62112
Code English
GUAIFENESIN [INN]
Common Name English
1,2-PROPANEDIOL, 3-(2-METHOXYPHENOXY)- (+/-)-
Systematic Name English
GUAIFENESIN [ORANGE BOOK]
Common Name English
GUAIFENESIN [WHO-DD]
Common Name English
GUAIFENSIN
Common Name English
GUAIACOL GLYCERYL ETHER
Systematic Name English
GUAIPHENESIN
Common Name English
GUAIFENESIN [VANDF]
Common Name English
GUAIFENESIN COMPONENT OF MUCINEX DM
Common Name English
ROBITUSSIN
Brand Name English
GUAIFENESIN [USP]
Common Name English
Classification Tree Code System Code
WHO-VATC QR05CA03
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
NCI_THESAURUS C29767
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
CFR 21 CFR 522.1086
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
WHO-VATC QM03BX90
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
CFR 21 CFR 341.78
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
CFR 21 CFR 341.18
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
CFR 21 CFR 522.1085
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
WHO-ATC R05CA03
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
Code System Code Type Description
EPA CompTox
93-14-1
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
LACTMED
Guaifenesin
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
CAS
93-14-1
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
ChEMBL
CHEMBL980
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
PUBCHEM
3516
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
USP_CATALOG
1301007
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY USP-RS
RXCUI
5032
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C29081
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
WIKIPEDIA
GUAIFENESIN
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
DRUG BANK
DB00874
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
HSDB
3089
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
IUPHAR
7617
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
EVMPD
SUB07973MIG
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
MESH
D006140
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
MERCK INDEX
M5861
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY Merck Index
FDA UNII
495W7451VQ
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
INN
968
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
DRUG CENTRAL
1336
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY
ECHA (EC/EINECS)
202-222-5
Created by admin on Fri Jun 25 21:11:14 UTC 2021 , Edited by admin on Fri Jun 25 21:11:14 UTC 2021
PRIMARY